Kiora Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Equity Incentive Plan (Tables)

Equity Incentive Plan (Tables)

12 Months Ended

Dec. 31, 2017

Share Based Compensation Option And Incentive Plan [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

The following is a summary of stock option activity for the twelve months ended December 31, 2017 and 2016:

	Number of Options		Weighted- Average Exercise Price		Weighted-Average Contractual Life (In Years)
Outstanding at December 31, 2015		1,277,367	$	2.75		4.94
Granted		377,771		2.74		9.79
Exercised		(86,765)		0.65
Forfeited		(58,662)		3.31
Outstanding at December 31, 2016		1,509,711	$	2.85		5.04
Granted		568,450		1.39		9.41
Exercised		(61,078)		0.67
Expired		(92,630)		2.10
Forfeited		(31,450)		2.99
Outstanding at December 31, 2017		1,893,003	$	2.49		5.40
Exercisable at December 31, 2017		1,208,450	$	2.73		4.87
Vested and Expected to Vest at December 31, 2017		1,208,450	$	2.73		4.87

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

For the twelve months ended December 31, 2017 and 2016, the fair value of each option grant has been estimated on the date of grant using the Black-Scholes Option Pricing Model with the following weighted-average assumptions:

	2017			2016
Risk-Free Interest Rate		1.82	%		1.82	%
Expected Life		7.25 years			7.00 years
Expected Volatility		170	%		99	%
Expected Dividend Yield		0	%		0	%

Employee and Non Employee Service Share Based Compensation Allocation off Recognized Period Costs [Table Text Block]

The total stock-based compensation expense for employees and non-employees is included in the accompanying Consolidated Statements of Operations and as follows:

	Year Ended December 31
	2017		2016
Research and Development	$	193,688	$	46,288
General and Administrative		676,620		464,707
	$	870,308	$	510,995